Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., active and no longer recruiting.
Overview
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT05887492 by Tango Therapeutics, Inc., with 126 participants planned, started 2023-06-12 and due to reach its primary completion in 2026-09. Interventions recorded: TNG260, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSafety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Shares Tango Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Shares Tango Therapeutics, Pembrolizumab.
- TreatmentTNG456
- TreatmentTNG462